Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757605 | 0.88 | HSD17B10 (0.48) | KDM4ESMN1; SMN2PTGDR2ALDH1A1HSD17B10 | |
| SCHEMBL1758337 | 0.87 | PTGDR2 (0.49) | PTGDR2ALDH1A1HSD17B10LMNA | |
| SCHEMBL1757420 | 0.86 | PTGDR2 (0.51) | KDM4EKMT2AMEN1PTGDR2ALDH1A1 | |
| SCHEMBL1757971 | 0.86 | PTGDR2 (0.50) | PTGDR2ALDH1A1HTT | |
| SCHEMBL1758033 | 0.81 | KDM4E (0.46) | KDM4ESMN1; SMN2KMT2ATDP1MEN1 | |
| SCHEMBL1757632 | 0.77 | PTGDR2 (0.59) | KDM4ESMN1; SMN2KMT2ATDP1MEN1 | |
| SCHEMBL1757995 | 0.76 | PTGDR2 (0.78) | KDM4ESMN1; SMN2KMT2ATDP1MEN1 | |
| SCHEMBL1757545 | 0.76 | KMT2A (0.47) | KDM4ESMN1; SMN2KMT2ATDP1MEN1 | |
| SCHEMBL11605995 | 0.76 | KDM4E (0.59) | KDM4ESMN1; SMN2KMT2ATDP1MEN1 | |
| SCHEMBL1757981 | 0.74 | PTGDR2 (0.79) | KDM4ESMN1; SMN2KMT2ATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | KDM4E 4693/4885SMN1; SMN2 4493/4885KMT2A 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.